Previous 10 | Next 10 |
2024-02-12 08:27:22 ET More on Pre-market losers & stocks. Manchester United: Public Market Discount Manchester United: A Historic Giant Facing Valuation Challenges And Why It's Time To Sell Knives Are Out For Vuzix Corporation Manchester United appoints ...
2024-02-09 09:01:46 ET More on OKYO Pharma Seeking Alpha’s Quant Rating on OKYO Pharma Historical earnings data for OKYO Pharma Financial information for OKYO Pharma Read the full article on Seeking Alpha For further details see: OKYO Pharm...
OK-101 is the first IND clearance granted by FDA for a drug to begin clinical studies specifically to treat patients suffering with neuropathic corneal pain (NCP), a major unmet medical need The initial trial of OK-101 to treat NCP is designed as a randomized, placebo-controlled, double-m...
LONDON and NEW YORK, Jan. 31, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and for neuropathic corneal pain (NCP), a s...
2024-01-09 08:21:38 ET More on Pre-market losers $ stocks. Cyclacel Pharmaceuticals, Inc. (CYCC) Q3 2023 Earnings Call Transcript Cyclacel Pharmaceuticals announces registered direct and private placement offering Financial information for Aclarion, Inc. Seek...
Statistically significant drug effects were observed in FDA-recognized efficacy endpoints as early as the 15-day first visit after dosing Statistically significant improvement was observed in both a “sign” (total conjunctival staining) and two “symptoms” (burni...
LONDON and NEW YORK, Jan. 05, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and for neuropathic corneal pain, a severe ...
LONDON and NEW YORK, Dec. 04, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and for neuropathic corneal pain, a severe ...
2023-10-31 13:18:43 ET More on OKYO Pharma OKYO shares retreat 12% after rallying ahead of Phase 2 study update OKYO Pharma announces capital raise of $3.95M without any underwriter or agent Financial information for OKYO Pharma For further details see: O...
Pricing of a registered direct offering for $1.64M of 1,092,600 ordinary shares at an offering price of $1.50 per ordinary share Simultaneous extinguishment of $4.20M of payables by issuing 2,766,667 ordinary shares, at the offering price of $1.50 per ordinary share, m...
News, Short Squeeze, Breakout and More Instantly...
OKYO Pharma Limited Company Name:
OKYO Stock Symbol:
NASDAQ Market:
LONDON and NEW YORK, May 08, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases ...
LONDON and NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment disease...
LONDON and NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ:OKYO), a clinical-stage biopharmaceutical company developing...